Market capitalization | €112.69b |
Enterprise Value | €122.71b |
PER (TTM) P/E ratio | 20.83 |
EV/FCF (TTM) EV/FCF | 14.37 |
EV/Sales (TTM) EV/Sales | 2.85 |
P/S ratio (TTM) P/S ratio | 2.62 |
P/B ratio (TTM) P/B ratio | 1.52 |
Dividend yield | 4.18% |
Last dividend (FY23) | €3.76 |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
25 Analysts have issued a Sanofi forecast:
25 Analysts have issued a Sanofi forecast:
Dec '23 |
+/-
%
|
||
Turnover | 43,070 43,070 |
0%
0%
|
|
Gross income | 26,603 26,603 |
2%
2%
|
|
EBITDA | 14,034 14,034 |
4%
4%
|
EBIT (operating result) EBIT | 9,183 9,183 |
8%
8%
|
Net profit | 5,400 5,400 |
35%
35%
|
Figures in millions EUR.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Head office | France |
CEO | Paul Hudson |
Employees | 87,994 |
Founded | 1994 |
Website | www.sanofi.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.